Fosamax and Osteonecrosis of the Jaw: Examining the Evidence for Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Specific Exposure Concerns

The legacy of general health and science communication has long served to inform the public about a wide range of medical conditions, from rare cancers to common ailments. This foundational approach emphasizes the importance of understanding disease origins and risk factors within a broad context. In the domain of mass production, this heritage provides a critical framework for examining how specific exposures within industrial or pharmaceutical settings may relate to adverse health outcomes. The transition from general health awareness to a more focused occupational concern requires a careful shift in perspective, moving from population-level information to the scrutiny of particular agents and their potential links to harm. Within this context, the question of whether a widely prescribed medication, such as Fosamax, is associated with a serious condition like osteonecrosis of the jaw represents a natural extension of this investigative tradition. The concern here is not merely about general health risks, but about the specific exposure pathways and causal relationships that may exist in a production or clinical environment. This pivot allows for a rigorous examination of causation without prematurely invoking mechanistic explanations, instead focusing on the epidemiological and observational evidence that connects a specific exposure to a defined health outcome.

Understanding Fosamax and Its Mechanism of Action

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The drug works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk. However, a known adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation and diagnosis of ONJ typically involve exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, or delayed healing after dental procedures. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is based on clinical examination and imaging, with histopathology confirming necrotic bone. The multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanistic Pathways and Risk Factors for ONJ

The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. In the jaw, which has high bone remodeling rates due to constant mechanical stress and dental procedures, this suppression can impair the repair of microdamage and lead to avascular necrosis. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Clinical Trial Data

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4 titled "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that ONJ can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the warning does not provide specific guidance on the optimal duration of use, as the limitations of use state that the optimal duration has not been determined, and for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a known adverse event, its incidence in clinical trials was low and not significantly different from placebo, complicating direct causation.

Causation Considerations and Temporal Relationship

Causation-related considerations for affected patients require careful evaluation of the temporal relationship between Fosamax exposure and ONJ onset. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, post-marketing reports and case series have established a plausible link, particularly in patients with additional risk factors such as cancer, chemotherapy, or dental procedures. The timeline between exposure and documented harm can vary widely. ONJ may develop after months to years of bisphosphonate use, with risk increasing with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In some cases, symptoms can appear within days of starting the drug, though this is less common. The delayed healing after dental procedures is a common precipitating event, and the condition may be diagnosed only after a dental extraction or implant placement. For affected patients, establishing causation involves documenting the absence of other causes (e.g., radiation therapy, metastatic disease, or severe periodontal disease) and the temporal association with Fosamax use.

Summary and Clinical Implications

In summary, Fosamax is associated with an increased risk of ONJ, particularly in patients with additional risk factors. The prescribing information includes warnings about this risk, but the low incidence in clinical trials and variability in onset complicate definitive causation. Patients and healthcare providers should weigh the benefits of fracture prevention against the risk of ONJ, especially in those undergoing invasive dental procedures or with prolonged bisphosphonate use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk. It is approved for postmenopausal women, men with osteoporosis, glucocorticoid-induced osteoporosis, and Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

ONJ is a condition characterized by exposed, non-healing bone in the jaw that persists for more than eight weeks, often with pain, swelling, infection, or delayed healing after dental procedures. Diagnosis is based on clinical examination and imaging, with histopathology confirming necrotic bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does Fosamax cause osteonecrosis of the jaw?

Fosamax is associated with an increased risk of ONJ, particularly in patients with additional risk factors such as invasive dental procedures, cancer, chemotherapy, or prolonged bisphosphonate use. The prescribing information includes a warning about this risk, but clinical trials showed low incidence not significantly different from placebo, complicating direct causation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. Risk increases with longer exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ to develop after starting Fosamax?

The time to onset varies widely, from one day to several months after starting the drug, and ONJ may develop after months to years of use, with risk increasing with longer exposure. Most patients have relief after stopping, but some experience recurrence upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.